BCR-ABL tyrosine kinase inhibitor

This page covers all BCR-ABL tyrosine kinase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting BCR-ABL, BCR-ABL, SRC family kinases.

Targets

BCR-ABL · BCR-ABL, SRC family kinases

Marketed (2)

• Nilotinib 300 mg. · King Abdullah International Medical Research Center · Oncology
  Nilotinib is a tyrosine kinase inhibitor that selectively blocks BCR-ABL and other kinases to inhibit abnormal cell proliferation in chronic myeloid leukemia.
• Dasatinib Tablets · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Oncology
  Dasatinib is a tyrosine kinase inhibitor that blocks BCR-ABL and multiple other kinases involved in cancer cell proliferation and survival.

Phase 3 pipeline (1)

• Radotinib HCl · Il-Yang Pharm. Co., Ltd. · Oncology
  Radotinib HCl is a BCR-ABL tyrosine kinase inhibitor designed to block the abnormal protein that causes chronic myeloid leukemia (CML).